Information Provided By: 
Fly News Breaks for March 21, 2016
VRX, HZNP
Mar 21, 2016 | 09:25 EDT
Stifel reports that "many" have suggested that Horizon Pharma (HZNP) will, like Valeant (VRX), be hurt by increased backlash by PBMs and payers for its use of specialty pharmacies. But the firm says that Horizon has already been hit by sanctions from PBMs. The firm does not believe that Horizon has been abusive of the healthcare system or relies only on price increases for its growth. The firm keeps a $45 price target and Buy rating on the shares.
News For HZNP;VRX From the Last 2 Days
There are no results for your query HZNP;VRX
